within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CG02_Tazobactam;

model Tazobactam
  extends Pharmacolibrary.Drugs.ATC.J.J01CG02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01CG02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tazobactam is a beta-lactamase inhibitor, commonly used in combination with beta-lactam antibiotics like piperacillin to extend their spectrum of activity against resistant bacterial pathogens. It is approved and widely used in clinical practice for the treatment of various infections caused by susceptible organisms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single intravenous dose.</p><h4>References</h4><ol><li><p>Maneerot, T, et al., &amp; Pattharachayakul, S (2025). Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis. <i>Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis</i> 45(1) 57–61. DOI:<a href=\"https://doi.org/10.1177/08968608241241449\">10.1177/08968608241241449</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38666694/\">https://pubmed.ncbi.nlm.nih.gov/38666694</a></p></li><li><p>Dulhunty, JM, et al., &amp; Lipman, J (2024). Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. <i>JAMA</i> 332(8) 629–637. DOI:<a href=\"https://doi.org/10.1001/jama.2024.9779\">10.1001/jama.2024.9779</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38864155/\">https://pubmed.ncbi.nlm.nih.gov/38864155</a></p></li><li><p>van Duin, D, &amp; Bonomo, RA (2016). Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 63(2) 234–241. DOI:<a href=\"https://doi.org/10.1093/cid/ciw243\">10.1093/cid/ciw243</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27098166/\">https://pubmed.ncbi.nlm.nih.gov/27098166</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tazobactam;
